文献速递肝病

自身免疫性肝炎死亡风险增加:基于全国人群的组织病理学队列研究

Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-14

瑞典1969-2017年全国性队列研究纳入6,016例经肝活检诊断的自身免疫性肝炎成人及28,146名匹配对照,随访期间AIH组3,185例死亡(41.4/1000人年) vs 对照组10,477例(21.9/1000人年),10年累积死亡率32.3% vs 14.1%,调整HR 2.29(95%CI 2.17-2.41),肝硬化者HR 4.55(95%CI 3.95-5.25)。

要点

  • AIH患者10年累积死亡率为32.3%(95%CI 31.1-33.6),高于对照组的14.1%(95%CI 13.7-14.5)。
  • 调整后全因死亡HR为2.29(95%CI 2.17-2.41),随访≥20年风险仍持续升高。
  • 活检有肝硬化的AIH患者死亡HR为4.55(95%CI 3.95-5.25),门静脉高压和重叠胆汁淤积性肝病也与死亡相关。

核心结论

  • AIH与约2倍死亡风险增加相关,肝硬化、门静脉高压及重叠胆汁淤积性肝病者风险尤其高。

研究设计与样本

  • 瑞典1969-2017年全国性人群队列研究,纳入6,016例经肝活检诊断的AIH成人及28,146名匹配的普通人群对照。
  • AIH定义为医学诊断的AIH加上来自瑞典28个病理科中任一科的肝活检。
  • 通过Cox回归估计全因和特定病因死亡的HR,肝移植纳入主要结局死亡。

主要发现

  • 随访期间AIH组3,185例死亡(41.4/1000人年) vs 对照组10,477例(21.9/1000人年)。
  • 10年累积死亡发生率AIH组32.3%(95%CI 31.1-33.6) vs 对照组14.1%(95%CI 13.7-14.5)。
  • 调整后全因死亡HR 2.29(95%CI 2.17-2.41),随访≥20年仍升高。
  • 活检有肝硬化的AIH患者死亡HR 4.55(95%CI 3.95-5.25),有纤维化、无纤维化炎症或坏死者死亡率无差异。
  • AIH与心血管疾病死亡HR 1.27(95%CI 1.15-1.40)、肝病死亡HR 66.24(95%CI 48.19-91.03)、肝外恶性肿瘤死亡HR 1.69(95%CI 1.51-1.89)风险增加相关;兄弟姐妹比较中AIH个体死亡风险仍增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that may lead to cirrhosis and liver failure, but data on overall mortality in AIH are conflicting. METHODS: This was a nationwide population-based cohort study in Sweden from 1969-2017 of 6,016 adults with AIH and 28,146 matched general population reference individuals. AIH was defined by a combination of a medical diagnosis of AIH plus a liver biopsy from any of Sweden's 28 pathology departments. Through Cox regression, we estimated hazard ratios (HRs) for overall and cause-specific death. Liver transplant was included in our main outcome of death. RESULTS: During follow-up, 3,185 individuals with AIH died (41.4/1000 person-years) compared with 10,477 reference individuals (21.9/1000 person-years). The 10-year cumulative incidence of death was 32.3% (95%CI = 31.1-33.6) for AIH individuals and 14.1% (95%CI = 13.7-14.5) for reference individuals. This corresponded to an adjusted HR of 2.29 (95%CI = 2.17-2.41), which remained elevated ≥20 years follow-up. AIH individuals with cirrhosis on biopsy had a high risk of death (HR = 4.55; 95%CI = 3.95-5.25), while mortality in patients with fibrosis, inflammation without fibrosis, or necrosis did not differ. Portal hypertension and overlap with cholestatic liver diseases were also associated with death. AIH was associated with an increased risk of death from cardiovascular disease (HR = 1.27; 95%CI = 1.15-1.40), liver disease (HR = 66.24; 95%CI = 48.19-91.03) and extrahepatic malignancy (HR = 1.69; 95%CI = 1.51-1.89). In a sibling comparison, AIH individuals remained at increased risk of death. CONCLUSION: AIH is associated with a 2-fold increased risk of death. Risks were particularly high in individuals with cirrhosis, portal hypertension, and overlap with cholestatic liver disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sharma R, Verna EC, Söderling J, et al. Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. Clin Gastroenterol Hepatol. 2020. PMID: 33065308. doi:10.1016/j.cgh.2020.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。